Califf Nomination Adds New Dynamic, Maybe New Provisions, To FDA Reform Bills

The Pink Sheet –

This article on Dr. Califf’s nomination to be the next FDA Commissioner explores how his confirmation process could become entwined with the Senate HELP Committee’s drug development/FDA reform bill. Catalyst President Nancy Myers comments on the potential for the confirmation hearings to influence provisions in the legislation. She also offers her thoughts on the benefits of FDA having a confirmed, rather than Acting, commissioner – despite the fact that a Commissioner Califf could end up serving a shorter term than his predecessor, Peggy Hamburg, due to the presidential election in 2016.

(subscription required)

2018-05-24T23:17:08+00:00